A detailed history of Geode Capital Management, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,754,464 shares of AKBA stock, worth $8.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,754,464
Previous 4,536,292 4.81%
Holding current value
$8.7 Million
Previous $4.63 Million 35.62%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.94 - $1.55 $205,081 - $338,166
218,172 Added 4.81%
4,754,464 $6.28 Million
Q2 2024

Aug 09, 2024

BUY
$0.86 - $1.63 $2.34 Million - $4.43 Million
2,717,345 Added 149.39%
4,536,292 $4.63 Million
Q1 2024

May 13, 2024

BUY
$1.27 - $2.24 $21,916 - $38,655
17,257 Added 0.96%
1,818,947 $3.33 Million
Q4 2023

Feb 13, 2024

BUY
$0.8 - $1.28 $61,932 - $99,092
77,416 Added 4.49%
1,801,690 $2.23 Million
Q3 2023

Nov 13, 2023

SELL
$0.87 - $1.84 $42,371 - $89,613
-48,703 Reduced 2.75%
1,724,274 $1.97 Million
Q2 2023

Aug 11, 2023

BUY
$0.51 - $1.43 $46,144 - $129,384
90,479 Added 5.38%
1,772,977 $1.63 Million
Q4 2022

Feb 13, 2023

BUY
$0.25 - $0.58 $15,168 - $35,190
60,673 Added 3.74%
1,682,498 $970,000
Q3 2022

Nov 14, 2022

BUY
$0.3 - $0.46 $1,329 - $2,038
4,432 Added 0.27%
1,621,825 $512,000
Q2 2022

Aug 12, 2022

SELL
$0.32 - $0.67 $491,316 - $1.03 Million
-1,535,365 Reduced 48.7%
1,617,393 $571,000
Q1 2022

May 13, 2022

SELL
$0.72 - $2.93 $39,766 - $161,826
-55,231 Reduced 1.72%
3,152,758 $2.26 Million
Q4 2021

Feb 11, 2022

SELL
$2.26 - $3.34 $49,616 - $73,326
-21,954 Reduced 0.68%
3,207,989 $7.25 Million
Q3 2021

Nov 12, 2021

BUY
$2.35 - $3.88 $722,133 - $1.19 Million
307,291 Added 10.51%
3,229,943 $9.3 Million
Q2 2021

Aug 13, 2021

BUY
$2.83 - $4.2 $916,481 - $1.36 Million
323,845 Added 12.46%
2,922,652 $11.1 Million
Q1 2021

May 12, 2021

BUY
$2.92 - $5.06 $1.09 Million - $1.89 Million
374,236 Added 16.82%
2,598,807 $8.8 Million
Q4 2020

Feb 12, 2021

BUY
$2.22 - $3.78 $150,855 - $256,862
67,953 Added 3.15%
2,224,571 $6.23 Million
Q3 2020

Nov 13, 2020

BUY
$2.39 - $13.08 $131,232 - $718,209
54,909 Added 2.61%
2,156,618 $5.41 Million
Q2 2020

Aug 13, 2020

BUY
$6.67 - $13.58 $1.85 Million - $3.76 Million
276,943 Added 15.18%
2,101,709 $28.5 Million
Q1 2020

May 14, 2020

BUY
$4.1 - $10.24 $684,445 - $1.71 Million
166,938 Added 10.07%
1,824,766 $13.8 Million
Q4 2019

Feb 13, 2020

BUY
$3.16 - $6.73 $249,658 - $531,710
79,006 Added 5.0%
1,657,828 $10.5 Million
Q3 2019

Nov 12, 2019

BUY
$3.55 - $5.4 $283,037 - $430,536
79,729 Added 5.32%
1,578,822 $6.19 Million
Q2 2019

Aug 14, 2019

BUY
$4.1 - $8.05 $962,573 - $1.89 Million
234,774 Added 18.57%
1,499,093 $7.26 Million
Q1 2019

May 14, 2019

BUY
$5.41 - $8.73 $1.37 Million - $2.21 Million
252,775 Added 24.99%
1,264,319 $10.4 Million
Q4 2018

Feb 13, 2019

BUY
$5.39 - $9.15 $2.01 Million - $3.42 Million
373,594 Added 58.56%
1,011,544 $5.59 Million
Q3 2018

Nov 13, 2018

BUY
$7.44 - $10.65 $391,016 - $559,721
52,556 Added 8.98%
637,950 $5.63 Million
Q2 2018

Aug 14, 2018

BUY
$9.15 - $11.34 $321,704 - $398,703
35,159 Added 6.39%
585,394 $5.84 Million
Q1 2018

May 15, 2018

BUY
$9.53 - $15.68 $466,703 - $767,880
48,972 Added 9.77%
550,235 $5.24 Million
Q4 2017

Feb 13, 2018

SELL
$14.24 - $19.59 $778,272 - $1.07 Million
-54,654 Reduced 9.83%
501,263 $7.45 Million
Q3 2017

Nov 14, 2017

BUY
$13.06 - $19.67 $2.97 Million - $4.48 Million
227,736 Added 69.39%
555,917 $10.9 Million
Q2 2017

Aug 14, 2017

BUY
N/A
328,181
328,181 $4.72 Million

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $336M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.